The most common inhibitory neurotransmitter in the central nervous system.
|Drug||Drug Name||Drug Indication|
|DB00181||Baclofen||Baclofen is administered for the relief of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and associated pain and clonus, in addition to muscular rigidity [FDA label]. Patients receiving this drug should have reversible spasticity for baclofen to promote the restoration of residual function. This drug is not indicated in the treatment of skeletal muscle spasm caused by rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been determined and, therefore, baclofen is not recommended for these conditions [FDA label].|
|DB00230||Pregabalin||Pregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for adult patients with partial onset seizures [FDA label].|
|DB01080||Vigabatrin||For use as an adjunct in treatment resistant epilepsy, refractory complex partial seizures, and secondary generalized seizures. It is also used as monotherapy in infantile spasms in West syndrome.|
|DB08892||Arbaclofen Placarbil||Investigated for the treatment of spasticity in multiple sclerosis, acute back spasms, and GERD.|
|DB02530||gamma-Aminobutyric acid||Not Available|
|DB00996||Gabapentin||For the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.|